Eric Schmidt
Stock Analyst at Cantor Fitzgerald
(0.45)
# 3,954
Out of 4,761 analysts
41
Total ratings
18.52%
Success rate
-29.04%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eric Schmidt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRTA Prothena Corporation | Reiterates: Overweight | n/a | $15.56 | - | 1 | Feb 21, 2025 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Neutral | n/a | $47.91 | - | 4 | Feb 19, 2025 | |
| CDTX Cidara Therapeutics | Assumes: Overweight | n/a | $21.54 | - | 1 | Jan 27, 2025 | |
| INCY Incyte | Reiterates: Neutral | n/a | $72.11 | - | 6 | Jan 10, 2025 | |
| AGIO Agios Pharmaceuticals | Reiterates: Overweight | n/a | $35.22 | - | 4 | Dec 18, 2024 | |
| TNGX Tango Therapeutics | Reiterates: Overweight | n/a | $2.36 | - | 3 | Dec 5, 2024 | |
| ALMS Alumis | Reiterates: Overweight | n/a | $5.17 | - | 3 | Nov 14, 2024 | |
| BCAX Bicara Therapeutics | Initiates: Overweight | n/a | $13.00 | - | 1 | Oct 8, 2024 | |
| RNA Avidity Biosciences | Reiterates: Overweight | $96 | $31.12 | +208.48% | 4 | Sep 18, 2024 | |
| BLUE bluebird bio | Reiterates: Neutral | n/a | $4.08 | - | 2 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.60 | - | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $29.92 | - | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $292 | $140.64 | +107.62% | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $1.63 | - | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $370 | $484.24 | -23.59% | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.92 | - | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $0.62 | - | 1 | May 30, 2017 |
Prothena Corporation
Feb 21, 2025
Reiterates: Overweight
Price Target: n/a
Current: $15.56
Upside: -
CRISPR Therapeutics AG
Feb 19, 2025
Reiterates: Neutral
Price Target: n/a
Current: $47.91
Upside: -
Cidara Therapeutics
Jan 27, 2025
Assumes: Overweight
Price Target: n/a
Current: $21.54
Upside: -
Incyte
Jan 10, 2025
Reiterates: Neutral
Price Target: n/a
Current: $72.11
Upside: -
Agios Pharmaceuticals
Dec 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $35.22
Upside: -
Tango Therapeutics
Dec 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.36
Upside: -
Alumis
Nov 14, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.17
Upside: -
Bicara Therapeutics
Oct 8, 2024
Initiates: Overweight
Price Target: n/a
Current: $13.00
Upside: -
Avidity Biosciences
Sep 18, 2024
Reiterates: Overweight
Price Target: $96
Current: $31.12
Upside: +208.48%
bluebird bio
Sep 16, 2024
Reiterates: Neutral
Price Target: n/a
Current: $4.08
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.60
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $29.92
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $292
Current: $140.64
Upside: +107.62%
May 30, 2024
Initiates: Overweight
Price Target: n/a
Current: $1.63
Upside: -
Oct 17, 2023
Reiterates: Overweight
Price Target: $370
Current: $484.24
Upside: -23.59%
Oct 17, 2023
Downgrades: Neutral
Price Target: n/a
Current: $1.92
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: n/a
Current: $0.62
Upside: -